The gene-editing technology known as CRISPR has attracted much excitement and investor interest with its potential to someday treat diseases by fixing faulty copies of genes. But recently, a different approach called RNA editing, which could offer advantages over CRISPR, has been gaining ground in academic labs and start-ups, according to an article in Chemical & Engineering News (C&EN), the weekly newsmagazine of the American Chemical Society.
RNA editing uses an enzyme called ADAR to make precise edits to RNA, the shorter-lived cousin to DNA that acts as a blueprint for proteins. Researchers direct ADAR to specific RNAs with a guide sequence attached to the enzyme. Unlike CRISPR gene editing, the effects of RNA editing are reversible because cells are constantly making new copies of RNA. Therefore, RNA editing avoids the risks of permanent gene editing with CRISPR, writes Assistant Editor Ryan Cross, and could also be used to treat temporary conditions, such as pain or inflammation.
However, finding an easy way to control how ADAR makes its edits has been challenging. Researchers have tried chemically attaching ADAR to a guide RNA, adding an RNA-binding protein or even linking the catalytic portion of ADAR to the bacterial Cas9 enzyme used in CRISPR. However, these approaches require getting the modified enzymes into human cells. Some researchers are working on using human cells’ own ADAR for RNA editing, by introducing chemically modified guide RNAs that recruit the editing enzyme and direct it to specific RNAs. With researchers and investors becoming increasingly interested in this approach, RNA editing could someday give CRISPR a run for its money, Cross writes.
The article, “Watch out, CRISPR. The RNA editing race is on,” is freely available here.
Learn more: Interest in RNA editing heats up
The Latest on: RNA editing
[google_news title=”” keyword=”RNA editing” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: RNA editing
- ProQR defends its Axiomer IP portfolio from new challengeon April 19, 2024 at 12:48 pm
Dutch rare diseases biotech firm ProQR Therapeutics (Nasdaq: PRQR) saw its shares leap more than 11% to $2.07 today, after it announced its successful defense against opposition filed against a key ...
- News - Axiomer RNAon April 19, 2024 at 11:05 am
Dutch rare diseases biotech firm ProQR Therapeutics saw its shares leap more than 11% to $2.07 today, after it announced its successful defense against opposition filed against a key patent for its ...
- ProQR Achieves Successful Defense of New Challenge to its Axiomer™ IP Portfolioon April 19, 2024 at 4:01 am
LEIDEN, Netherlands & CAMBRIDGE, Mass., April 19, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today announced it has ...
- Korro Announces $70 Million Private Placementon April 18, 2024 at 7:30 am
Financing led by Deep Track Capital with participation from other leading healthcare investorsPro-forma cash and cash equivalents of ...
- RNA-editing drugs advance into clinical trialson April 17, 2024 at 5:00 pm
The company is set to start dosing patients with the disease shortly. A growing list of biotechs are setting their sights on similar RNA-editing opportunities (Table 1).
- Can a Blood Test Diagnose Depression and Bipolar Disorder?on April 15, 2024 at 5:28 am
SYNLAB and ALCEDIAG recently launched the first blood test to assist in mental health diagnosis in France. The test is aimed at differentiating bipolar disorders from depression. The news may be ...
- Novel Insights into RNA Modification in HIV-1 Revealedon April 11, 2024 at 8:41 pm
Chemical modification in the HIV-1 RNA genome is now confirmed to be key to the virus’s ability to survive and thrive.
- Study confirms how RNA chemical modifications benefit HIV-1on April 11, 2024 at 10:10 am
A chemical modification in the HIV-1 RNA genome whose function has been a matter of scientific debate is now confirmed to be key to the virus's ability to survive and thrive after infecting host cells ...
- MEGA CRISPR: Engineering Better Immunotherapies with RNA Editingon March 31, 2024 at 5:00 pm
“Our years of experience on gene editing at the DNA level makes us realize that this technology, while very powerful, still has some intrinsic challenges, which could possibly only be addressed if we ...
- Korro Bio Earns Buy Rating on Promising RNA Editing Technology for AATD Treatmenton March 27, 2024 at 10:26 pm
Kapoor notes that Korro Bio’s RNA base editing technology, KRRO-110, presents a less risky alternative to DNA base editing, which is permanent and comes with higher risks. By contrast ...
via Bing News